Sandoz Group

Sandoz Group Inventory

The Inventory of Sandoz Group (SDZ.SW) as of Oct 27, 2026 is 2.85 B USD. In the previous year, Inventory was 3.40 B USD — a change of -16.38% (lower).

Inventory

2.85 BUSD

YoY

-16.38%

Last updated:

Inventory of Sandoz Group is 2025 2.85 B USD. Inventory of Sandoz Group was 2024 3.40 B USD. It decreases by -16.38% lower compared to the previous year.

The Sandoz Group Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2020
2.08 B USD
Jan 1, 2021
1.83 B USD
Jan 1, 2022
1.97 B USD
Jan 1, 2023
2.76 B USD
Jan 1, 2024
3.40 B USD
Jan 1, 2025
2.85 B USD
The Sandoz Group Inventory history
YEARInventoryYoY
2.85 BUSD-16.38%
3.40 BUSD+23.21%
2.76 BUSD+40.51%
1.97 BUSD+7.52%
1.83 BUSD-12.01%
2.08 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sandoz Group Stock analysis

What does Sandoz Group do? Sandoz Group AG generates revenue through its Generics and Biosimilars businesses. The Generics business develops, manufactures, and markets active ingredients and finished dosage forms of small molecule pharmaceuticals, as well as anti-infective finished dosage forms and active pharmaceutical ingredients. The Biosimilars business develops, manufactures, and markets protein-based biological products similar to already approved biological medicines. Sandoz serves customers worldwide across therapeutic areas including cardiovascular, central nervous system, oncology, anti-infectives, pain, and respiratory treatments. Its product portfolio covers all major treatment areas for patient care. The company's Generics business focuses on small molecule pharmaceuticals and anti-infectives, while Biosimilars targets protein-based biological products. Both segments serve global healthcare markets with products for various therapeutic areas. Sandoz's customers are healthcare providers and institutions worldwide that require pharmaceutical solutions for diverse medical conditions. Sandoz Group AG's revenue streams come from the sale of generics and biosimilars across all therapeutic areas. The company's products are distributed globally to healthcare systems and providers who treat patients in cardiovascular, central nervous system, oncology, anti-infectives, pain, and respiratory conditions. The firm's business model relies on developing and commercializing both small molecule pharmaceuticals and biological products to meet global healthcare needs. Sandoz Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sandoz Group stock

Inventory of Sandoz Group is 2.85 B USD in 2025.

Inventory of Sandoz Group changed from 3.40 B USD to 2.85 B USD, representing a -16.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Sandoz Group since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Sandoz Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sandoz Group

All Key Metrics — Sandoz Group